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Abstract
Background: Gyejibongnyeong-hwan (GJBNH) is one of the most popular Korean medicine formulas for menstrual
pain of dysmenorrhea. The concept of blood stagnation in Korean medicine is considered the main factor of
causing abdominal pain, or cramps, during menstrual periods. To treat the symptoms, GJBNH is used to fluidify the
stagnated blood and induce the blood flow to be smooth, reducing pain as the result. The purpose of this trial is
to identify the efficacy of GJBNH in dysmenorrhea caused by blood stagnation.
Methods: This study is a multi-centre, randomised, double-blind, controlled trial with two parallel arms: the group
taking GJBNH and the group taking placebo. 100 patients (women from age 18 to 35) will be enrolled to the trial.
Through randomization 50 patients will be in experiment arm, and the other 50 patients will be in control arm. At
the second visit (baseline), all participants who were already screened that they fulfil both the inclusion and the
exclusion criteria will be randomised into two groups. Each group will take the intervention three times per day
during two menstrual cycles. After the treatment for two cycles, each patient will be followed up during their 3
rd,
4
th and 5
th menstrual cycles. From the screening (Visit 1) through the second follow-up (Visit 6) the entire process
will take 25 weeks.
Discussion: This trial will provide evidence for the effectiveness of GJBNH in treating periodical pain due to
dysmenorrhea that is caused by blood stagnation. The primary outcome between the two groups will be
measured by changes in the Visual Analogue Score (VAS) of pain. The secondary outcome will be measured by the
Blood Stagnation Scale, the Short-form McGill questionnaire and the COX menstrual symptom scale. Analysis of
covariance (ANCOVA) and repeated measured ANOVA will be used to analyze the data analysis.
Trial registration: Current Controlled Trials: ISRCTN30426947
Background
Dysmenorrhea is a very common medical condition in
women worldwide. The prevalence varies from 45% to
95% of all women depending on its definition [1]. In
Korea, 78.3% of all adolescent girls have dysmenorrhea
during their menstrual periods [2]. The most common
symptom of dysmenorrhea is abdominal pain, or cramp.
It is not only painful but interferes with daily activities,
and it has been the leading cause of recurrent short-
term school absence [3].
The most prominent physiological cause of dysmenor-
rhea in allopathic medicine is the production of uterine
prostaglandins. Endometrial cells release prostaglandins
when they are deciduous. The released prostaglandins
stimulate myometrial contractions and cause ischemia.
This results in abdominal pain, which has been the
source of difficulties that women have to cope with in
their daily lives.
But the explanation for the pain is different in Tradi-
tional Korean Medicine. In Traditional Korean Medi-
cine, the causes of sicknesses are classified according to
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lists diagnose the cause of the sickness by symptoms
and signs and prescribe the appropriate remedy.
The most common factor causing dysmenorrhea in
Traditional Korean Medicine is blood stagnation in the
uterus. ‘Flow’ is a very important concept in Traditional
Korean Medicine. If the flow of qi and blood inside the
both is smooth, the body is healthy without any dis-
eases. But if the flow is interrupted, it causes pain. This
can be applicable to qi and blood. Blood stagnation
means obstructed blood flow, and a woman experien-
cing dysmenorrhea can be explained by blood stagnation
in her body. The signs of blood stagnation are getting
bruised easily, tender abdominal pain, etc.
The first treatment of dysmenorrhea in allopathic med-
icine is an over-the-counter drug, especially non-steroidal
anti-inflammatory drugs (NSAIDs) such as Ibuprofen,
Naproxen, Mefenamic, etc. [3,4]. These drugs, however,
have failed to show effect in 20% to 25% of women, and
moreover some women complain about digestive disor-
ders while taking the drug. In this case, Korean herbal
medicine can be a plausible alternative [5].
Gyejibongnyeong-hwan (GJBNH) is one of the most
popular Korean medicine formulas for periodical pain
due to dysmenorrhea. GJBNH fluidifies blood to induce
smooth blood flow and reduce pain [6]. However, the
evidence of the effect of GJBNH in treating dysmenorrea
has been reported mostly in the form of case reports. In
the era of evidence medicine, high quality evidence is
mandatory for a medical formula to be proven effective.
The purpose of this trial is to identify the efficacy of
GJBNH in dysmenorrhea caused by blood stagnation.
Methods
Objectives & Hypothesis
Objectives
1) Clinically significant improvement in the severity
of pain caused by dysmenorrhea
2) Correlation between blood stagnation level and
pain severity
Hypothesis
The hypothesis is that GJBNH will reduce menstrual
pain more effectively than placebo after taking the inter-
vention–GJBNH or the placebo–for two menstrual
cycles.
Setting
This trial is a randomized, double-blind, parallel group,
placebo-controlled phase IV trial. There are three inves-
tigational sites: Oriental Medicine Obstetrics and Gyne-
cology Clinic of Kyung Hee Medical Center in Seoul,
Obstetrics and Gynecology Clinic of Won Kwang Orien-
tal Hospital in Gunpo, and Obstetrics and Gynecology
Clinic of Kyung Won Gil Oriental Medical Hospital of
Kyung Won University in Incheon, Korea. Participants
will be treated as outpatients in these sites. Before the
beginning of the trial, the protocol of the trial has been
approved by the Institutional Review Board (IRB). All
participants will take GJBNH or placebo for two men-
strual cycles (about eight weeks). They will be followed
up during three menstrual cycles. It takes five menstrual
cycles (about 20 weeks) from baseline to finish. The
total span from screening (visit 1) to finish (2
nd follow-
up) can vary according to the participant’sp e r i o d .F i g -
ure 1 is an overview of this trial.
Participants
Inclusion Criteria
The inclusion criteria are as follow (Table 1).
Exclusion Criteria
The exclusion criteria of this trial are described in Table
2.
Interventions
Gyejibongnyeong-hwan (GJBNH) is a Traditional Kor-
ean Medicine formula. It consists of Cinnamomi ramu-
lus, Poria, Moutan cortex, Persicae semen,a n dPaeoniae
radix. Gyejibongnyeong-hwan is a small brown ball-like
tablet. A single dose of GJBNH is one pouch in which
there are 20~30 tablets. The placebo medicine is made
of lactose, corn starch and food coloring and has a simi-
lar appearance, shape, weight, taste, and color as
GJBNH. The treatment drug and placebo will be pro-
vided by Hanpoong Pharm & Foods Co., Ltd.
Rescue medication
Ten pain killer pills will be given during each treatment
cycle as rescue medication. If the participant can not
endure the pain, she can take the rescue medication.
But all participants should not take any pain-killer
except given by the investigator. If the participant takes
any other drug than what is given from the trial, it
should be described in the case-report form (CRF). Any
participant taking drugs that can influence the outcome
such as NSAIDs or oral contraceptive pills will be
excluded from the trial.
Outcomes
Primary outcome
The primary outcome in this study is the change in the
Visual Analogue Scale (VAS) of average menstrual pain
between the baseline (Visit 2) and after the treatment
(Visit 4). A 100 mm VAS will be used to assess average
level of pain during the menstrual period.
Secondary outcome
The secondary outcome measures include the VAS (the
maximum pain during the menstrual period), the Blood
Park et al. Trials 2012, 13:3
http://www.trialsjournal.com/content/13/1/3
Page 2 of 6Stagnation Scale, the Short Form McGill Pain Question-
naire [7], and the Cox Menstrual Symptom Scale [8].
The quantity of pain killer pills taken during the men-
strual period would be recorded at every visit. Heart
Rate Variability (HRV) will also be measured.
Safety assessment
All participants will report any adverse event she had
while taking the intervention at every visit. Every
adverse event will be described in the CRF. If the
adverse event is severe and associates with the trial, the
Visit 2 
Visit 1 Kyung Hee Univ. 
Hospital, Seoul
Randomization; 100 participants
GJBNH Group
n=50
Placebo Group
n=50
Inclusion/Exclusion criteria check, Screening Procedure
Menstrual Cycle
Before Enrollment
Kyung Won Univ. 
Hospital, Incheon
Won Kwang 
Univ. Hospital, 
Gunpo
Informed Consent 
1st Menstrual Cycle
After Enrollment
Outcome Assessment at Baseline
Treatment
Visit 3 
Visit 4 
Visit5
Efficacy and Safety Assessment
Visit 6
2nd Menstrual Cycle
3 times/day
During 1 menstrual 
cycle
Take 3 times/day
During 1 menstrual 
cycle
3 times per day
During 1 menstrual 
cycle
3 times/day
During 1 menstrual 
cycle
Efficacy and Safety Assessment Follow-Up
Screening
3rd Menstrual Cycle
4th & 5th Menstrual Cycle
Efficacy and Safety Assessment
Efficacy and Safety Assessment
Enrollment
Figure 1 Study flow chart.
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priate treatment will be given to her. For safety assess-
ment, a liver function test, blood cell count test,
physical examination, and urine analysis will be carried
out at Visit 4.
Sample size
The primary outcome in this trial is the change of the
Visual Analogue Score (VAS) of average pain in the
menstrual period between the baseline (Visit 2) and
after treatment (Visit 4). The hypothesis is
H0:δ = 1 − 2=0
H1 : δ = 1 − 2  = 0
Δ1: The change of VAS score between Visit 4 and
baseline in GJBNH group
Δ2: The change of VAS score between Visit 4 and
baseline in placebo control
As a reference, we have chosen the study of Choi et.
al. [6] and Yeh LL [9]. The mean (± standard deviation,
SD) change of the VAS in GJBNH group (n = 13) was
2.42 (± 2.04) and those in placebo control group (n =
38) was 1.08 (± 2.14). We used the mean difference
between groups, 1.34 (= 2.42-1.08), as a clinically signifi-
cant improvement worth to detect and 2.12 as its pooled
standard deviation. With 5% of two-sided significance
level and 80% of statistical power, we needed to ran-
domly assign fifty participants in each group considering
approximately 20% of drop-out rate.
Randomization
Participants will be given a random number at Visit 2.
When a participant makes the second visit to the trial
site, the investigator will connect to the Medical
Research Collaboration Center (MRCC) web site run by
S e o u lN a t i o n a lU n i v e r s i t yH o s p i t a lw h i c hi sc o m m i s -
sioned for the allocation process in this trial. To rando-
mize, the investigator will connect to the MRCC website
(http://mrcc.snuh.org) and input patient’sn u m b e ra n d
birthday, and confirm that the patient fulfil the inclusion
and the exclusion criteria. Then, a random number is
generated. No one except the researcher at the MRCC
can know whether the number indicates treatment
group or placebo group, and all participants, investiga-
tors, and monitors are blinded.
Statistical method
Efficacy analysis will be performed for both ITT (inten-
tion-to treat, all randomly assigned participants) and PP
(per-protocol, participants completed the trial without
any protocol deviations) data sets. To compare the dif-
ferences of the average changes of the VAS between the
experimental arm and the control arm, the Short Form
McGill Pain Questionnaire score, the blood stagnation
score, the Cox menstrual score from the baseline (Visit
2) to after the treatment (Visit 4) between two groups,
and analysis of covariance (ANCOVA) using the base-
line score as a covariate will be used.
For the variables which measure the autonomic nerve
system (HF, high frequency; LF, low frequency; HF/LF
ratio), similar methods described above or their corre-
sponding non-parametric analysis will be performed as
appropriate.
For ITT analysis, missing data will be imputed by MI
(Multiple Imputation) method using SAS/MI procedure.
The safety data set will include the participants who
take the intervention at least once. For safety analysis,
physical examination and self-reported adverse event
will be compared by the chi-square test. In addition, the
results of liver function tests, blood cell count and urine
analysis will be analyzed using the same methods as
Table 1 Inclusion criteria of GJBNH study
Inclusion criteria
1. Female aged 18 to 35 years.
2. Women whose period cycle was 30 ± 3 days during last 3 months.
3. Women who have menstrual pain (dysmenorrhea) over 6 degrees by the Visual Analogue Scale (VAS) at screening.
4. Women who are diagnosed with blood stagnation by two oriental medical gynecologic specialists.
5. Have given a written informed consent form
6. Have given a written informed consent form for genetic study.
Table 2 Exclusion criteria of GJBNH study
Exclusion criteria
1. A woman who has major neuro-psychiatric disorder (schizophrenia, epilepsy, alcohol abuse, anorexia, etc.) or has history of major neuro-
psychiatric disorder.
2. A woman who is planning to have a baby.
3. A woman who is taking anti-depressant, anti-serotonin, barbiturate, or psychotropic drugs.
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results into normal or abnormal according to their
respective normal ranges. The chi-square test will be
used to compare the differences between the groups.
Monitoring
The Center for Clinical Research and Genomics (CCRG;
the CRO) is responsible for monitoring. Monitoring will
begin after the first participant completes the whole pro-
cess of this study. Every institution where the trial is
being conducted will be monitored while this trial is in
process using the Standard Operation Procedure (SOP)s.
Ethical Consideration
The trial is conducted to the Declaration of Helsinki
2008 and/or the regulations of the “Good Clinical Prac-
tice” principles in the Korea Food & Drug
Administration.
The Institutional Review Board (IRB) has approved of
this clinical trial at all institution before the participant
recruitment. The reference numbers are KOMC IRB
2008-07 (IRB of Kyung Hee Oriental Medical Center,
approved on 18
th of Aug 2008), WONSBHB IRB 2009-
02 (IRB of Wonkwang University Sanbon Oriental Med-
ical Center, approved on 24
th of Feb 2009) and 09-101
(IRB of Kyungwon Gil Oriental Medical Hospital
approved on 2
nd of Feb 2009). Prior to undertaking any
study-related procedures, all participants will provide
written informed consent.
Discussion
It is not a facile task to design a trial to identify the effi-
cacy of Traditional Korean herbal formula, because the
sickness has to be diagnosed according to various symp-
toms and signs, and in Traditional Korean Medicine
herbal formula has to be decided according to different
diagnosis. The symptoms and signs are critical, not the
name of the disease–this led the inclusion and exclusion
criteria to be as diverse and thorough as the subjects of
the trial.
Dysmenorrhea has typical symptoms and characteris-
tics and thus can be categorized into types based on cer-
tain symptoms. The types vary according to diseases,
and in this case dysmenorrhea can be defined to four
Table 3 Summary of assessments at procedures
Screening Treatment period Follow-up
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Informed Consent x
History Taking
1 x
Demographic information taking
2 x
Pregnancy Check
3 xxxxx
Blood Stagnation Diagnosis
4 x xxx
VAS
5 x xxxxx
McGill Questionnaire x x x x x x
Cox Menstrual Scale x x x x x x
Physical Examination x x
Liver function test
6 xx
Blood Cell Count
7 xx
Urinalysis
8 xx
Safety Assessment
9 xxxx
HRV x x x x
Compliance x x
￿ Visit 1; Informed consent and screening procedure
￿Visit 2; Randomization and outcome assessment for baseline
￿Visit 4; Outcome assessment for primary objective
x: Item has to be carried out for the visit
1 history of drug taking for the past one month, allergy and disease history, obstetric history, menarche and menstrual period, etc.
2 date of birth, age, height, and weight.
3 medical examination by interview.
4 a scale for diagnosing blood stagnation, has not been published.
5 the 100 mm visual analogue scale. The mean and the maximum pain during the menstrual period
6 AST, ALT, BUN, creatinine, ALP
7 WBC, RBC, hemoglobin, hematocrit, Platelet
8 protein, glucose, urobilinogen, ketone, RBC, WBC squamous cell
9 medical examination and self-report of adverse event
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blood and qi deficiency and weak constitution of liver
and kidney [10]. The remedies vary according to the
cause, but blood stagnation is the most assessable
among these types while the other types are difficult to
evaluate. This is why we have selected blood stagnation
as the cause of dysmenorrhea that we treat. There are
many Traditional Korean Medicine formula treating
blood stagnation to cure dysmenorrhea, but GJBNH is
the most common and widely used with rare adverse
events.
Determining the sample size is another challenge.
There are few references, so we used two reference
papers to calculate the sample size.
Gyejibongnyeong-hwan as one of Traditional Korean
Medicine formula has been widely used for thousands of
years. But, the evidence supporting this formula is rare.
We are hoping that this trial will provide high quality
evidence and that the protocol for this trial will be a
reference in design further clinical trials.
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